代谢组学在感染性疾病中的研究进展

doi:10.3760/cma.j.issn.1007-1245.2024.08.017

摘要/Abstract

摘要：

感染性疾病是全球严重的公共卫生问题之一，对人类健康危害性极大。近年来，代谢组学逐步应用于感染性疾病的研究中，以了解小分子水平的宿主-病原体相互作用，通过基于核磁共振（NMR）或基于质谱（MS）的代谢组学筛选疾病特异性生物标志物，为预防疾病及探索病因、发病机制等方面带来新的机遇。本综述讨论了代谢组学技术在生物标志物筛选和病毒、细菌、寄生虫感染等感染性疾病中代谢物的发现以及免疫代谢组学的应用，以期为感染性疾病的诊断研究提供新的依据。

关键词:

代谢组学, 感染性疾病, 生物标志物, 免疫保护, 综述

Abstract:

Infectious diseases are one of the serious public health problems in the world, which are very harmful to human health. In recent years, metabolomics has been gradually applied to the research of infectious diseases to understand host-pathogen interactions at the small molecular level. By screening disease specific biomarkers through metabolomics based on nuclear magnetic resonance (NMR) or mass spectrometry (MS), new opportunities have been brought for disease prevention and exploration of etiology and pathogenesis. This review discusses the application of metabolomics in screening biomarkers, finding metabolites in infectious diseases such as virus, bacteria, and parasite infections, and the application of immunometabolomics, in order to provide new evidences for the diagnosis of infectious diseases.

Key words:

Metabolomics, Infectious diseases, Biomarkers, Immunoprotection, Review

王霞赛海芳.

代谢组学在感染性疾病中的研究进展 [J]. 国际医药卫生导报, 2024, 30(8): 1312-1316.

Wang Xia, Sai Haifang.

Research progress of metabolomics in infectious diseases [J]. International Medicine and Health Guidance News, 2024, 30(8): 1312-1316.

参考文献

[1] 包晨,刘超,刘倩,等.泛凋亡和感染性疾病研究进展[J].华中科技大学学报(医学版),2023,52(4):569-573.DOI:10.3870/j.issn.1672-0741.2023.04.023.
[2] 李祥,宁永忠.感染性疾病抢先预防研究进展[J].中国感染控制杂志,2023,22(7):853-855.DOI:10.12138/j.issn.1671- 9638.20233640.
[3] 杜丽敏,张洁,赵凤芹.中性粒细胞载脂蛋白在感染性疾病应用的临床进展[J].中国实验诊断学,2023,27(5):626-631.DOI:10.3969/j.issn.1007-4287.2023.05.030.
[4] Tounta V, Liu Y, Cheyne A, et al. Metabolomics in infectious diseases and drug discovery[J]. Mol Omics, 2021, 17(3):376-393. DOI: 10.1039/d1mo00017a.
[5] Vinayavekhin N, Homan EA, Saghatelian A. Exploring disease through metabolomics[J]. ACS Chem Biol, 2010, 5(1):91-103. DOI: 10.1021/cb900271r.
[6] Elias C, Nkengasong JN, Qadri F. Emerging infectious diseases - learning from the past and looking to the future[J]. N Engl J Med, 2021, 384(13):1181-1184. DOI: 10.1056/NEJMp2034517.
[7] Fu J, Zhu F, Xu CJ, et al. Metabolomics meets systems immunology[J]. EMBO Rep, 2023, 24(4):e55747. DOI: 10.15252/embr.202255747.
[8] Lydon EC, Ko ER, Tsalik EL. The host response as a tool for infectious disease diagnosis and management[J]. Expert Rev Mol Diagn, 2018, 18(8):723-738. DOI: 10.1080/14737159.2018.1493378.
[9] Babu M, Snyder M. Multi-omics profiling for health[J]. Mol Cell Proteomics, 2023, 22(6):100561. DOI: 10.1016/j.mcpro.2023.100561.
[10] Pacchiarotta T, Deelder AM, Mayboroda OA. Metabolomic investigations of human infections[J]. Bioanalysis, 2012, 4(8):919-925. DOI: 10.4155/bio.12.61.
[11] Kim DH, Creek DJ. What role can metabolomics play in the discovery and development of new medicines for infectious diseases?[J]. Bioanalysis, 2015, 7(6):629-631. DOI: 10.4155/bio.15.5.
[12] Nguyen TD, Lan Y, Kane SS, et al. Single-cell mass spectrometry enables insight into heterogeneity in infectious disease[J]. Anal Chem, 2022, 94(30):10567-10572. DOI: 10.1021/acs.analchem.2c02279.
[13] Quinn RA. Integrating microbiome and metabolome data to understand infectious airway disease[J]. Am J Respir Crit Care Med, 2017, 196(7):806-807. DOI: 10.1164/rccm.201704-0671ED.
[14] Zurfluh S, Baumgartner T, Meier MA, et al. The role of metabolomic markers for patients with infectious diseases: implications for risk stratification and therapeutic modulation[J]. Expert Rev Anti Infect Ther, 2018, 16(2):133-142. DOI: 10.1080/14787210.2018. 1426460.
[15] Williams AA, Sitole LJ, Meyer D. HIV/HAART-associated oxidative stress is detectable by metabonomics[J]. Mol Biosyst, 2017, 13(11):2202-2217. DOI: 10.1039/c7mb00336f.
[16] Sitole LJ, Williams AA, Meyer D. Metabonomic analysis of HIV-infected biofluids[J]. Mol Biosyst, 2013, 9(1):18-28. DOI: 10.1039/c2mb25318f.
[17] Sitole LJ, Tugizimana F, Meyer D. Multi-platform metabonomics unravel amino acids as markers of HIV/combination antiretroviral therapy-induced oxidative stress[J]. J Pharm Biomed Anal, 2019, 176:112796. DOI: 10.1016/j.jpba.2019.112796.
[18] Ivanov AV, Valuev-Elliston VT, Ivanova ON, et al. Oxidative stress during HIV infection: mechanisms and consequences[J]. Oxid Med Cell Longev, 2016,2016:8910396. DOI: 10.1155/2016/8910396.
[19] Guo H, Wang Q, Ghneim K, et al. Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication[J]. Nat Immunol, 2021, 22(4):423-433. DOI: 10.1038/s41590-021-00898-1.
[20] Mann AE, O'Connell LM, Osagie E, et al. Impact of HIV on the oral microbiome of children living in Sub-Saharan Africa, determined by using an rpoC gene fragment metataxonomic approach[J]. Microbiol Spectr, 2023, 11(4):e0087123. DOI: 10.1128/spectrum.00871-23.
[21] Yu M, Zhu Y, Cong Q, et al. Metabonomics research progress on liver diseases[J]. Can J Gastroenterol Hepatol, 2017,2017:8467192. DOI: 10.1155/2017/8467192.
[22] Gouveia LR, Santos JC, Silva RD, et al. Diagnosis of coinfection by schistosomiasis and viral hepatitis B or C using 1H NMR-based metabonomics[J]. PLoS One, 2017, 12(8):e0182196. DOI: 10.1371/journal.pone.0182196.
[23] Hou Q, Duan ZJ. Metabonomic window into hepatitis B virus-related hepatic diseases[J]. World J Hepatol, 2016, 8(1):1-8. DOI: 10.4254/wjh.v8.i1.1.
[24] Huang G, Xie S, Wang M, et al. Metabolite profiling analysis of hepatitis B virus-induced liver cirrhosis patients with minimal hepatic encephalopathy using gas chromatography-time-of-flight mass spectrometry and ultra-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry[J]. Biomed Chromatogr, 2023, 37(1):e5529. DOI: 10.1002/bmc.5529.
[25] Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection[J]. Nat Rev Immunol, 2022, 22(1):19-32. DOI: 10.1038/s41577-021- 00549-4.
[26] 杨逸鑫,彭芳.基于代谢组学的中医药防治肝纤维化的研究进展[J].中南药学,2023,21(1):155-160.DOI:10.7539/j.issn.1672-2981.2023.01.025.
[27] Nomair AM, Madkour MA, Shamseya MM, et al. Profiling of plasma metabolomics in patients with hepatitis C-related liver cirrhosis and hepatocellular carcinoma[J]. Clin Exp Hepatol, 2019, 5(4):317-326. DOI: 10.5114/ceh.2019.89478.
[28] Sarfaraz MO, Myers RP, Coffin CS, et al. A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C[J]. Clin Transl Med, 2016, 5(1):33. DOI: 10.1186/s40169-016-0109-2.
[29] 钟凯苑,杨秋萍,郭微,等.不同孕周母亲及其新生儿血氨基酸代谢谱变化特点[J].国际医药卫生导报,2021,27(9):1316-1321.DOI:10.3760/cma.j.issn.1007-1245.2021. 09.012.
[30] Shanmuganathan M, Sarfaraz MO, Kroezen Z, et al. A cross-platform metabolomics comparison identifies serum metabolite signatures of liver fibrosis progression in chronic hepatitis C patients[J]. Front Mol Biosci, 2021, 8:676349. DOI: 10.3389/fmolb.2021.676349.
[31] Yang J, Wang D, Li Y, et al. Metabolomics in viral hepatitis: advances and review[J]. Front Cell Infect Microbiol, 2023, 13:1189417. DOI: 10.3389/fcimb.2023.1189417.
[32] Jia H, Liu C, Li D, et al. Metabolomic analyses reveal new stage-specific features of COVID-19[J]. Eur Respir J, 2022, 59(2):2100284. DOI: 10.1183/13993003.00284-2021.
[33] 马坤,王道斌,李树军.支气管肺泡灌洗液中细胞学对儿童肺部疾病诊治研究进展[J].国际医药卫生导报,2023,29(8):1049-1052.DOI:10.3760/cma.j.issn.1007-1245.2023. 08.004.
[34] Byeon SK, Madugundu AK, Garapati K, et al. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study[J]. Lancet Digit Health, 2022, 4(9):e632-e645. DOI: 10.1016/S2589-7500(22)00112-1.
[35] Arjmand B, Alavi-Moghadam S, Parhizkar-Roudsari P, et al. Metabolomics signatures of SARS-CoV-2 infection[J]. Adv Exp Med Biol, 2022,1376:45-59. DOI: 10.1007/5584_2021_674.
[36] Sindelar M, Stancliffe E, Schwaiger-Haber M, et al. Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity[J]. Cell Rep Med, 2021, 2(8):100369. DOI: 10.1016/j.xcrm.2021. 100369.
[37] Salinas JL, Kissinger JC, Jones DP, et al. Metabolomics in the fight against malaria[J]. Mem Inst Oswaldo Cruz, 2014, 109(5):589-597. DOI: 10.1590/0074-0276140043.
[38] Mahmud I, Garrett TJ. Mass spectrometry techniques in emerging pathogens studies: COVID-19 perspectives[J]. J Am Soc Mass Spectrom, 2020, 31(10):2013-2024. DOI: 10.1021/jasms.0c00238.
[39] Wang X, Xu G, Liu X, et al. Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection[J]. Cell Mol Immunol, 2021, 18(10):2313-2324. DOI: 10.1038/s41423-021-00754-0.
[40] du Preez I, Luies L, Loots DT. The application of metabolomics toward pulmonary tuberculosis research[J]. Tuberculosis (Edinb), 2019, 115:126-139. DOI: 10.1016/j.tube.2019.03.003.
[41] Luies L, du Preez I, Loots DT. The role of metabolomics in tuberculosis treatment research[J]. Biomark Med, 2017, 11(11):1017-1029. DOI: 10.2217/bmm-2017-0141.
[42] Chandra P, Coullon H, Agarwal M, et al. Macrophage global metabolomics identifies cholestenone as host/pathogen cometabolite present in human Mycobacterium tuberculosis infection[J]. J Clin Invest, 2022, 132(3):e152509. DOI: 10.1172/JCI152509.
[43] Tsamouri MM, Durbin-Johnson BP, Culp WTN, et al. Untargeted metabolomics identify a panel of urinary biomarkers for the diagnosis of urothelial carcinoma of the bladder, as compared to urolithiasis with or without urinary tract infection in dogs[J]. Metabolites, 2022, 12(3):200. DOI: 10.3390/metabo12030200.
[44] Lussu M, Camboni T, Piras C, et al. 1H NMR spectroscopy-based metabolomics analysis for the diagnosis of symptomatic E. coli-associated urinary tract infection (UTI)[J]. BMC Microbiol, 2017, 17(1):201. DOI: 10.1186/s12866-017-1108-1.
[45] Nevedomskaya E, Pacchiarotta T, Artemov A, et al. (1)H NMR-based metabolic profiling of urinary tract infection: combining multiple statistical models and clinical data[J]. Metabolomics, 2012, 8(6):1227-1235. DOI: 10.1007/s11306-012-0411-y.
[46] Lam CW, Law CY, Sze KH, et al. Quantitative metabolomics of urine for rapid etiological diagnosis of urinary tract infection: evaluation of a microbial-mammalian co-metabolite as a diagnostic biomarker[J]. Clin Chim Acta, 2015, 438:24-28. DOI: 10.1016/j.cca.2014.07.038.